Paris-based preventive health startup Lucis has successfully raised $8.5 million in a seed funding round led by General Catalyst. The company aims to democratize access to proactive health monitoring, providing individuals with a clear understanding of their biological data before symptoms arise. This investment will fuel its mission to shift Europe's healthcare paradigm from reactive treatment to proactive, data-driven prevention.
Challenging the Reactive Healthcare Model
Europe's healthcare systems are predominantly structured to treat illnesses after symptoms manifest, a costly approach given the prevalence of chronic conditions. Many diseases like heart disease and diabetes present early warning signs in routine blood tests years in advance. However, a structured and accessible way for people to interpret and act on these signals has been largely absent.
Lucis was founded by Maxime Berthelot, Baptiste Debever, and Max Guerois to address this critical gap in preventive care. The platform provides members with regular health check-ups through certified medical laboratories, translating complex biological data into actionable insights. This model empowers individuals to take control of their health by understanding their bodies on a deeper level.
A Data-Driven Approach to Wellness
The platform operates by tracking over 180 biomarkers from blood draws, offering a comprehensive overview of an individual's health status. These results are reviewed by a multidisciplinary medical team, which leverages artificial intelligence to highlight priority signals and monitor trends over time. This combination of clinical expertise and advanced technology ensures users receive accurate and relevant information.
Instead of receiving a static and technical report, users access a dynamic dashboard with a prioritized action plan. This guidance is organized around five key pillars: nutrition, supplements, physical activity, sleep and recovery, and mental health. By focusing on practical lifestyle adjustments, Lucis helps translate complex health data into tangible improvements in well-being.
Strategic Funding for European Expansion
The $8.5 million seed funding was led by General Catalyst, with significant participation from Y Combinator, Kima Ventures, Motier Ventures, and others. This robust financial backing signals strong investor confidence in Lucis's vision to build the infrastructure for modern preventive health. The capital is designated to accelerate the company's growth and technological development across the continent.
With the new funds, Lucis plans to accelerate its rollout in its current markets of France, the UK, Ireland, and Portugal, while preparing for entry into new territories. The investment will also be used to expand its network of partner laboratories and clinicians. Furthermore, the company will continue to develop its AI-enabled preventive analysis and support platform to enhance user outcomes.
Positioning for the Future of Health
CEO Maxime Berthelot emphasized that Lucis is a preventive tool designed to complement, not replace, traditional medical care. The company's mission is to give people clarity on key health indicators, empowering them to make informed decisions alongside their physicians. To date, the platform has served 3,000 customers and completed over 500,000 clinical tests.
Lucis distinguishes itself from competitors through its AI-driven evolution tracking and a holistic, five-pillar approach to personalization. The company is committed to a structured, public health–aligned model that avoids a self-diagnosis or gadget-focused mindset. This focus on clinical validity and long-term data tracking aims to set a new standard in consumer health technology.
This latest funding round marks a significant milestone for Lucis, positioning it to scale its innovative approach to preventive health across Europe. By integrating certified laboratory analysis, medical expertise, and a user-friendly platform, the company is at the forefront of a crucial shift toward proactive wellness. Lucis is well-equipped to make personalized, preventive healthcare an accessible reality for a broader population.